Boston Scientific Corp (BSX)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 16,747,000 | 14,240,000 | 12,682,000 | 11,888,000 | 9,913,000 |
| Total current assets | US$ in thousands | 6,920,000 | 6,514,000 | 5,760,000 | 6,317,000 | 6,694,000 |
| Total current liabilities | US$ in thousands | 6,399,000 | 4,933,000 | 3,803,000 | 4,274,000 | 3,681,000 |
| Working capital turnover | 32.14 | 9.01 | 6.48 | 5.82 | 3.29 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $16,747,000K ÷ ($6,920,000K – $6,399,000K)
= 32.14
The working capital turnover ratio for Boston Scientific Corp has displayed a notable increasing trend over the past five years. Starting at 3.29 in December 2020, the ratio has shown consistent improvement to reach 32.14 by December 2024. This signifies that the company's efficiency in managing its working capital has significantly increased over the period, with each dollar of working capital generating higher levels of revenue. Such a substantial rise in the working capital turnover ratio indicates enhanced efficiency in utilizing current assets to support sales growth and operational activities. This positive trend suggests that Boston Scientific Corp has been effectively managing its working capital to drive operational performance and potentially improve overall financial health.
Peer comparison
Dec 31, 2024